Phosphodiesterase 5 inhibitors

被引：22
|
作者：
Stamford, AW [1 ]
机构：
[1] Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA
来源：
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 37 | 2002年 / 37卷
关键词：
D O I：
10.1016/S0065-7743(02)37007-6
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
引用
收藏
页码：53 / 64
页数：12
相关论文
共 50 条
  • [21] Recreational use and misuse of phosphodiesterase 5 inhibitors
    Smith, KM
    Romanelli, F
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2005, 45 (01) : 63 - 75
  • [22] Novel indications for phosphodiesterase type 5 inhibitors
    Rosenkranz, Stephan
    Caglayan, Evren
    Erdmann, Erland
    MEDIZINISCHE KLINIK, 2007, 102 (08) : 617 - 630
  • [23] Phosphodiesterase 5 inhibitors in male sexual dysfunction
    Kuthe, A
    CURRENT OPINION IN UROLOGY, 2003, 13 (05) : 405 - 410
  • [24] Editorial: Tachyphylaxis and phosphodiesterase type 5 inhibitors
    Steers, WD
    JOURNAL OF UROLOGY, 2002, 168 (01): : 207 - 207
  • [25] Optimizing response to phosphodiesterase type 5 inhibitors
    Sadovsky R.
    Current Sexual Health Reports, 2007, 4 (1) : 1 - 6
  • [26] The use of phosphodiesterase 5 inhibitors with concomitant medications
    Corona, G.
    Razzoli, E.
    Forti, G.
    Maggi, M.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2008, 31 (09) : 799 - 808
  • [27] Phosphodiesterase 5 inhibitors in vascular systemic disorders
    Allanore, Yannick
    JOINT BONE SPINE, 2012, 79 (04) : 338 - 340
  • [28] Phosphodiesterase-5 Inhibitors: Future Perspectives
    Konstantinos, Giannitsas
    Petros, Perimenis
    CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (30) : 3540 - 3551
  • [29] Phosphodiesterase type 5 inhibitors and kidney disease
    Afsar, Baris
    Ortiz, Alberto
    Covic, Adrian
    Gaipov, Abduzhappar
    Esen, Tarik
    Goldsmith, David
    Kanbay, Mehmet
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2015, 47 (09) : 1521 - 1528
  • [30] Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors
    Jackson, G
    AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (12B): : 32M - 36M
12345